All Oncology News

European Commission Approves Pembrolizumab/Lenvatinib for Advanced or Recurrent Endometrial Cancer

November 29th 2021

Gina Mauro

The European Commission has granted an approval to the combination of pembrolizumab and lenvatinib for the treatment of patients with advanced or recurrent endometrial carcinoma who have disease progression on or following prior platinum-containing therapy in any setting and who are not eligible for curative surgery or radiation.

CG0070 Plus Pembrolizumab Shows Early Tolerability and Activity in BCG-Unresponsive Non–Muscle Invasive Bladder Cancer

November 29th 2021

Caroline Seymour

The combination of CG0070 and pembrolizumab was well tolerated and demonstrated early signals of activity in patients with Bacille Calmette-Guérin-unresponsive non–muscle invasive bladder cancer.

Experts Review Key Data From ESMO Congress 2021

November 29th 2021

Brittany Lovely

Several leading experts discussed a variety of tumor types set to influence the next wave of investigative directions and change the standard of care for patients in abstracts at the European Society for Medical Oncology Congress 2021.

Lisocabtagene Maraleucel Displays Durable Remissions in Relapsed/Refractory LBCL

November 29th 2021

Caroline Seymour

Lisocabtagene maraleucel demonstrated durable responses and a favorable safety profile in patients with relapsed/refractory large B-cell lymphoma.

Novel Therapies Propel the Paradigms of Breast and Gynecologic Cancers Forward

November 28th 2021

Jessica Hergert

Panelists discuss the latest advances in targeting HER2-positive breast cancer, the rapidly evolving landscape of triple-negative breast cancer, the role of maintenance therapy in ovarian cancer, and recent updates in the treatment of patients with endometrial and cervical cancers.

Investigators Set Their Sets on Novel Targets in Genitourinary Malignancies

November 27th 2021

Caroline Seymour

Manojkumar Bupathi, MD, MS, shares the main highlights from the meeting, which centered on frontline, second, and later-line treatment of metastatic urothelial carcinoma and metastatic renal cell carcinoma.

Frontline Cabozantinib Plus Atezolizumab Shows Favorable Survival in Advanced HCC

November 26th 2021

Caroline Seymour

The combination of cabozantinib and atezolizumab led to a statistically significant improvement in progression-free survival and a numerical improvement in overall survival vs sorafenib as frontline treatment in patients with advanced hepatocellular carcinoma, according to findings from the first planned analysis of the phase 3 COSMIC-312 trial.

Multigene Panel Testing Identifies Actionable Germline Mutations in Newly Diagnosed Endometrial Cancer

November 26th 2021

Courtney Marabella

Investigators identified potentially actionable germline variants in 10% of unselected women with newly diagnosed endometrial cancer, supporting the use of upfront multigene panel testing for all in the population.

Katona Highlights the Hallmarks of Hereditary Diffuse Gastric Cancer

November 25th 2021

OncLive Staff

Bryson Katona, MD, discusses the hallmarks of hereditary diffuse gastric cancer.

Practice Recommendations Make Room for Telemedicine in Oncology Care

November 25th 2021

Brittany Lovely

Telemedicine solidified its role as a new standard in patient care during the COVID-19 pandemic.

FDA Grants Fast Track Status to Arfolitixorin for Metastatic Colorectal Cancer

November 24th 2021

Kristi Rosa

The FDA has granted a fast track designation to arfolitixorin as a potential therapeutic option for patients with metastatic colorectal cancer.

New ASTRO President Calls Attention to In-Person Meetings, Remaining Challenges, and Ongoing Research in Radiation Oncology

November 24th 2021

Jessica Hergert

Jeff M. Michalski, MD, MBA, FASTRO, shares his presidential goals for ASTRO, the success of the hybrid 2021 ASTRO Annual Meeting, and remaining questions in radiation oncology that research efforts are poised to address.

FDA Greenlights Maribavir for Select Post-Transplant Recipients With CMV

November 24th 2021

Kristi Rosa

The FDA has approved maribavir for the treatment of adult and pediatric patients aged 12 years and older weighing at least 35 kg who have post-transplant cytomegalovirus infection that does not respond to available antiviral treatment.

World Health Organization Taps Sylvester in Global Fight Against Cervical Cancer

November 24th 2021

Sylvester Comprehensive Cancer Center will provide a leading role in the collaborative effort to eliminate the preventable disease that kills thousands of women around the world.

Dr. Erickson on PARP Inhibitor Maintenance Therapy in BRCA-Mutated Ovarian Cancer

November 24th 2021

Britt Erickson, MD

Britt Erickson, MD, discusses the benefit of PARP inhibitor maintenance therapy in patients with BRCA-mutated ovarian cancer.